搜索
Centessa Pharmaceuticals PLC
CNTA添加自选
39.595USD
-0.015-0.04%
交易中 （美东）报价延迟15分钟
5.91B总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.04%
5天
-0.19%
1月
+0.29%
6月
+48.30%
今年开始到现在
+58.32%
1年
+201.10%
TradingKey Centessa Pharmaceuticals PLC股票评分
单位: USD 更新时间: 2026-05-12操作建议
Centessa Pharmaceuticals PLC当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名47/383位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价44.00。中期看，股价处于上升通道。近一个月，市场表现一般，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Centessa Pharmaceuticals PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Centessa Pharmaceuticals PLC亮点
亮点风险
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
业绩高增长
公司营业收入稳步增长，连续3年增长118.88%
业绩增长期
公司处于发展阶段，最新年度总收入15.00M美元
利润高增长
公司净利润处于行业前列，最新年度总收入15.00M美元
估值低估
公司最新PE估值-22.31，处于3年历史低位
机构加仓
最新机构持股150.25M股，环比增加7.40%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值7.03K
活跃度降低
近期活跃度降低，过去20天平均换手率0.75
分析师目标
根据
13
位分析师
持有
评级
44.000
目标均价
+11.14%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Centessa Pharmaceuticals PLC新闻
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Centessa Pharmaceuticals PLC简介
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
公司代码CNTA
公司Centessa Pharmaceuticals PLC
CEOSaha (Saurabh)
网址https://www.centessa.com/
相关品种
